Head-to-head · WeighScore
Claya vs Direct Meds
By GLP-1 ScorecardUpdated
Score comparison
Direct Meds has the higher recorded score — 77.6/100 to 62.8/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Claya | Direct Meds |
|---|---|---|
| WeighScore | 62.8/100 | 77.6/100 |
| Grade | C | C+ |
| Site position | #298 | #35 |
| Semaglutide | $299/mo (compounded) | $249/30 days sublingual · $297/mo injectable |
| Tirzepatide | $299/mo (compounded) | $299/30 days sublingual · $399/mo injectable |
| Coverage | Coverage not published | Not publicly listed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #298 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
What to consider
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Site position #35 · C+
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Strengths
- Injection and sublingual preparations have separately published prices
- Pricing page advertises medication, evaluation, supplies, shipping and nurse access
- Both semaglutide and tirzepatide are listed
- Checked semaglutide campaign states $147 initially, then $297 monthly
What to consider
- Compounded preparations are not FDA-approved products or assumed equivalent across routes
- No-subscription FAQ wording conflicts with the agreement's 30-day recurring charges
- Renewal cancellation requires 48-hour notice; initial-order cancellation has a separate conditional 24-hour window
- Assigned prescribing practice, dispensing pharmacy and selected longer-plan total need confirmation
- Checked campaign excludes Mississippi and Louisiana; confirm state eligibility
Featured provider
Direct Meds
Direct Meds scores 77.6/100 (C+). Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.